Pathos AI
CHICAGO, Illinois, United States · Artificial Intelligence, Biotechnology, Health Care
Pathos is an AI-enabled biotechnology company focused on re-engineering drug development, leveraging the power of technology to bring precision medicine to patients through partnerships with pharmaceutical companies. Pathos has raised over $100 million to accelerate the development of precision medicines and to expand its platform, combining computational approaches across multimodal real-world da
Key facts
- Headquarters
- CHICAGO, Illinois, United States
- Employees
- 98
- Industries
- Artificial Intelligence, Biotechnology, Health Care
- Status
- Private
- Website
- pathos.com
- Company page
Recent activity at Pathos AI
- : Pathos AI, Inc. has closed $237 million in Series E financing, led by Bristol Myers Squibb, to scale their AI-driven drug development platform and advance their oncology pipeline.
- : Pathos AI and AstraZeneca Enter Co-Exclusive Licensing Agreement for AZD4241 in ER+ Breast Cancer Research.
- : Pathos AI
- : Pathos AI
- : Pathos AI raised $62M in a Series C funding round led by New Enterprise Associates to enhance AI-driven drug development efforts.
- : Pathos AI
Pathos AI funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2026 | Series E | $237.0M |
| May 2025 | Venture | $283.0M |
| Nov 2024 | Venture | $62.0M |
| Oct 2024 | Series C | $62.0M |
| Mar 2023 | Venture | $20.0M |
Leadership
- Eric Schadt, Chief Scientific Officer
- Jens Renstrup, Chief Medical Officer
- Ryan Fukushima, Executive Officer
Verified email and direct lines for Pathos AI’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Pathos AI files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Pathos AI in the news
- Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline - Yahoo Finance (Oct 23, 2026)
- AI drug firm Pathos raises $237 million, pushing valuation to $3 billion - STAT (Oct 23, 2026)
- BMS leads Pathos AI's $237M series E alongside Alzheimer's link-up - Fierce Biotech (Oct 23, 2026)
- Pathos AI Licenses Alphamab's TROP2/HER3 Bispecific ADC, JSKN016 - BioPharm International (Aug 04, 2026)
- Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions - Business Wire (Oct 23, 2026)
- Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents - MedCity News (Aug 04, 2026)
- Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC - BioSpace (Aug 03, 2026)
- M&A Roundup: Pathos AI Enter’s Licensing Agreements with AstraZeneca & Alphamab Oncology, Curium Enters Merger Agreement with Lantheus - Pharmaceutical Executive (Aug 04, 2026)
Companies similar to Pathos AI
- Kordata Dynamics · Artificial Intelligence, Biotechnology, Health Care, Health Diagnostics, Machine Learning, Therapeutics
- Carta Healthcare · Artificial Intelligence, Biotechnology, Health Care, Health Diagnostics, Machine Learning
- Aignostics · Artificial Intelligence, Biotechnology, Health Care, Health Diagnostics, Machine Learning
- Pharos · Artificial Intelligence, Biotechnology, Health Care, Health Diagnostics, Machine Learning
- BPGbio · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Therapeutics
About Pathos AI: questions and answers
What does Pathos AI do?
Pathos is an AI-enabled biotechnology company focused on re-engineering drug development, leveraging the power of technology to bring precision medicine to patients through partnerships with pharmaceutical companies. Pathos has raised over $100 million to accelerate the development of precision medicines and to expand its platform, combining computational approaches across multimodal real-world da
Where is Pathos AI headquartered?
Pathos AI is headquartered in CHICAGO, Illinois, United States.
How many employees does Pathos AI have?
Pathos AI has about 98 employees.
Has Pathos AI raised funding?
Yes. Fundz has recorded 5 funding events for Pathos AI. The most recent, Series E of $237.0M, was in Oct 2026.
What is the latest news on Pathos AI?
On Oct 23, 2026, Pathos AI, Inc. has closed $237 million in Series E financing, led by Bristol Myers Squibb, to scale their AI-driven drug development platform and advance their oncology pipeline.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy